Alkem Laboratories, based in Mumbai, has announced the launch of its generic empagliflozin and combinations under the brand name Empanorm, which will reduce the medication's cost by about 80% when compared to originator medicines. This change is intended to improve accessibility for millions of people suffering from type 2 diabetes, chronic kidney disease (CKD), and chronic heart failure (HF).

Empagliflozin is a commonly prescribed SGLT-2 (Sodium-Glucose Co-Transporter-2) inhibitor that has been shown to help manage diabetes and improve the health of the heart and kidneys. Alkem's version of the medicine is bioequivalent to the innovator formulations, providing the same efficacy and safety.

To address concerns about counterfeit pharmaceuticals, Alkem has added an anti-counterfeit security band to the package of Empanorm. Furthermore, patient education has been a significant priority, with diabetes care information supplied in Hindi and English, accompanied by infographics. QR codes on the package enable patients and carers to access prescribing information and educational resources in 11 languages, including diabetes, heart failure, and chronic kidney disease.

In a patient-centric design enhancement, Alkem has produced a much smaller pill size than previous innovator medications, improving ease of use.

The company has developed a novel approach to diabetes management, developing a variety of empagliflozin combination medicines suited to specific patient needs. When empagliflozin is mixed with linagliptin, it creates a mechanism that works together to manage glucose in more than one way. Also, Empagliflozin Duo and Alsita E contain both empagliflozin and sitagliptin. Using these two drugs together improves the effectiveness of therapy by using different but complementary ways to manage blood sugar levels. Furthermore, Empagliflozin M combines empagliflozin and metformin, expanding the treatment choices accessible. These formulations, taken together, highlight the company's commitment to personalised care by offering doctors diverse tools for improving treatment results for patients with type 2 diabetes.

Dr. Vikas Gupta, CEO of Alkem Laboratories, emphasised the significance of this launch for boosting treatment accessibility, saying, "As we expand and strengthen our chronic portfolio, the introduction of generic empagliflozin in India is an important milestone." This internationally approved chemical has changed diabetes therapy by providing extra benefits for chronic renal disease and cardiovascular health. We intend to make this medication broadly available by using Alkem's robust distribution network, thereby boosting treatment accessibility and health outcomes for people across the country." 

Mumbai, India— Alkem Laboratories has announced the launch of its generic empagliflozin and combinations under the brand name Empanorm, which will reduce the medication's cost by about 80% compared to originator goods. This change is intended to improve accessibility for millions of people suffering from type 2 diabetes, chronic kidney disease (CKD), and chronic heart failure (HF).

Empagliflozin is a commonly prescribed SGLT-2 (Sodium-Glucose Co-Transporter-2) inhibitor that has been shown to help manage diabetes and improve the health of the heart and kidneys. Alkem's version of the medicine is bioequivalent to the innovator formulations, providing the same efficacy and safety.

To address concerns about counterfeit pharmaceuticals, Alkem has added an anti-counterfeit security band to the package of Empanorm. Furthermore, patient education has been a significant priority, with diabetes care information supplied in Hindi and English, accompanied by infographics. QR codes on the package enable patients and carers to access prescribing information and educational resources in 11 languages, including diabetes, heart failure, and chronic kidney disease.

In a patient-centric design enhancement, Alkem has produced a much smaller pill size than previous innovator medications, improving ease of use.

The company has developed a novel approach to diabetes management, developing a variety of empagliflozin combination medicines suited to specific patient needs. Empagliflozinzin combines empagliflozin with linagliptin, resulting in a synergistic mechanism that addresses glucose management from various aspects. Meanwhile, Empagliflozin Duo and Alsita E combine empagliflozin and sitagliptin, increasing therapy efficacy by harnessing complementary mechanisms to control blood sugar levels. Furthermore, Empagliflozin M combines empagliflozin and metformin, expanding the treatment choices accessible. These formulations, taken together, highlight the company's commitment to personalised care by offering doctors diverse tools for improving treatment results for patients with type 2 diabetes.

Dr. Vikas Gupta, Chief Executive Officer of Alkem Laboratories, emphasised the significance of this launch for boosting treatment accessibility, saying, "As we expand and strengthen our chronic portfolio, the introduction of generic empagliflozin in India is an important milestone." This internationally approved chemical has changed diabetes therapy by providing extra benefits for chronic renal disease and cardiovascular health. We intend to make this medication broadly available by using Alkem's robust distribution network, thereby boosting treatment accessibility and health outcomes for people across the country."